Market Madness Showdown: AbbVie vs. GlaxoSmithKline

In honor of March Madness, The Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series gets under way with a tough matchup between AbbVie , Abbott's recently spun-off pharmaceutical division, and Big Pharma giant GlaxoSmithKline. To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the following video.

In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.

The article Market Madness Showdown: AbbVie vs. GlaxoSmithKline originally appeared on Fool.com.

David Williamson, Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.